Indeed, PPARγ agonists have been shown to suppress monocyte elaboration of inflammatory cytokines (Jiang et al, 1998) and to inhibit IL-1β-induced expression of IL-8 in colon cancer cell lines (Su et al, 1999). Here, CXCL8 is linked to malignant colon neoplasm.